Hua Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hua Wang has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
Nuojin Guo
Department of Endocrinology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China
4 shared publicationsHao Zhang
Department of Endocrinology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China
3 shared publicationsHongmei Zhao
Department of Endocrinology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China
3 shared publicationsAyinaer Jieensihan
Department of Endocrinology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China
2 shared publicationsHekai Shi
Department of Bariatric and Metabolic Surgery, Fudan University Affiliated Huadong Hospital, Shanghai, China
2 shared publications- Jin Tao
Medical College of Soochow University
2 shared publications
Latest Publications
- 10 July 2024
- Published by Zhejiang University Press in Journal of Zhejiang University-SCIENCE B
- Vol. 25 (7) , 568-580
Human umbilical cord mesenchymal stem cells attenuate diabetic nephropathy through the IGF1R-CHK2-p53 signalling axis in male rats with type 2 diabetes mellitus
Diabetes mellitus (DM) is a disease syndrome characterized by chronic hyperglycaemia. A long-term high-glucose environment leads to reactive oxygen species
- 10 July 2024
- Published by Zhejiang University Press in Journal of Zhejiang University-SCIENCE B
- Vol. 25 (7) , 568-580
Human umbilical cord mesenchymal stem cells attenuate diabetic nephropathy through the IGF1R-CHK2-p53 signalling axis in male rats with type 2 diabetes mellitus
Diabetes mellitus (DM) is a disease syndrome characterized by chronic hyperglycaemia. A long-term high-glucose environment leads to reactive oxygen species
- Open Access
- 8 July 2024
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 15, 1381322
Causal relationships of lifestyle behaviours and body fat distribution on diabetic microvascular complications: a Mendelian randomization study
Objectives: To determine the causal correlations of lifestyle behaviours and body fat distribution on diabetic microvascular complications through a Mendelian Randomization (MR).Methods: Genetic variants significantly associated with lifestyle behaviours, abdominal obesity, generalized obesity and diabetic microvascular complications were extracted from the UK Biobank (UKB) and FinnGen. The inverse variance weighted (IVW) method was regarded as the primary method. The main results were presented in odds ratio (OR) per standard deviation (SD) increase, and a series of sensitivity analyses were also conducted to validate the stability of the results.Results: There was a positive causal correlation between smoking and the development of diabetic retinopathy (OR = 1.16; 95%CI: 1.04–1.30; p = 0.01). All of the indicators representing abdominal obesity had a statistically significant causal association with diabetic microvascular complications. Concerning generalized obesity, there were significant causal associations of body mass index (BMI) on diabetic nephropathy (OR = 1.92; 95%CI: 1.58–2.33; p < 0.001), diabetic retinopathy (OR = 1.27; 95%CI: 1.15–1.40; p < 0.001), and diabetic neuropathy (OR = 2.60; 95%CI: 1.95–3.45; p < 0.001). Other indicators including leg fat mass (left), and arm fat mass (left) also had a significant positive causality with diabetic microvascular complications.Conclusion: Our findings suggested that smoking has a genetically causal association with the development of diabetic retinopathy rather than diabetic nephropathy and diabetic neuropathy. In addition, both abdominal obesity and generalized obesity are risk factors for diabetic microvascular complications. To note, abdominal obesity represented by waist circumference (WC) is the most significant risk factor.
- 8 July 2024
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 15, 1381322
Open AccessCausal relationships of lifestyle behaviours and body fat distribution on diabetic microvascular complications: a Mendelian randomization study
Objectives: To determine the causal correlations of lifestyle behaviours and body fat distribution on diabetic microvascular complications through a Mendelian Randomization (MR).Methods: Genetic variants significantly associated with lifestyle behaviours, abdominal obesity, generalized obesity and diabetic microvascular complications were extracted from the UK Biobank (UKB) and FinnGen. The inverse variance weighted (IVW) method was regarded as the primary method. The main results were presented in odds ratio (OR) per standard deviation (SD) increase, and a series of sensitivity analyses were also conducted to validate the stability of the results.Results: There was a positive causal correlation between smoking and the development of diabetic retinopathy (OR = 1.16; 95%CI: 1.04–1.30; p = 0.01). All of the indicators representing abdominal obesity had a statistically significant causal association with diabetic microvascular complications. Concerning generalized obesity, there were significant causal associations of body mass index (BMI) on diabetic nephropathy (OR = 1.92; 95%CI: 1.58–2.33; p < 0.001), diabetic retinopathy (OR = 1.27; 95%CI: 1.15–1.40; p < 0.001), and diabetic neuropathy (OR = 2.60; 95%CI: 1.95–3.45; p < 0.001). Other indicators including leg fat mass (left), and arm fat mass (left) also had a significant positive causality with diabetic microvascular complications.Conclusion: Our findings suggested that smoking has a genetically causal association with the development of diabetic retinopathy rather than diabetic nephropathy and diabetic neuropathy. In addition, both abdominal obesity and generalized obesity are risk factors for diabetic microvascular complications. To note, abdominal obesity represented by waist circumference (WC) is the most significant risk factor.
- 8 September 2023
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 79 (11) , 1465-1474
Comparison of the efficacy and safety of hypoglycemic treatments in patients with non-alcoholic fatty liver disease and type-2 diabetes: a systematic review and Bayesian network analysis
Purpose The association between non-alcoholic fatty liver disease (NAFLD) and metabolic disorders, especially type-2 diabetes (T2DM), has been proven to be bidirectional. Hypoglycemic agents may be promising treatments for those disorders. However, there is currently no approved hypoglycemic therapy for NAFLD. In this review, we aimed to compare the efficacy and safety of twelve different hypoglycemic treatments in patients with NAFLD and T2DM. Methods We systematically screened randomized controlled trials (RCTs) published from March 2013 to March 2023 by searching PubMed, Embase, Medline, and Web of Science without any language restriction. We registered this project on the PROSPERO website: https://www.crd.york.ac.uk/PROSPERO/(ID: CRD42023429701). All subsequent analyses were performed under the registered protocol. The mean difference (MD) and 95% confidence interval (95% CI) were adapted to evaluate the effect size of the treatment. The surface under the cumulative sorting curve (SUCRA) was used to rank the efficacy of the included treatments. Results We included 19 trials involving 1212 patients in total. Insulin plus glucagon-like peptide-1 receptor agonist (GLP1RA) combination therapy was probably the most effective treatment for reducing weight and body mass index (BMI) (SUCRA: 0.93 and 1.00). Thiazolidinediones (TZD) were probably the most effective treatment for reducing glycosylated hemoglobin (HbA1c) and γ-glutamyltranspeptidase (γ-GGT) levels (SUCRA: 0.78 and 0.97). Sodium-glucose cotransporter 2 inhibitors (SGLT2i) had the highest probability of presenting good therapeutic efficacy in reducing triglyceride (TG) levels (SUCRA: 0.72). The most common adverse reactions were gastrointestinal disorders, mainly after the administration of GLP1RA, and mild hypoglycemia, which was closely related to the use of insulin. Conclusion GLP1RA plus insulin combination therapy, GLP1RA, SGLT2i, and TZD may be the most effective therapeutic methods for patients with NAFLD and T2DM.
- 8 September 2023
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 79 (11) , 1465-1474
Comparison of the efficacy and safety of hypoglycemic treatments in patients with non-alcoholic fatty liver disease and type-2 diabetes: a systematic review and Bayesian network analysis
Purpose The association between non-alcoholic fatty liver disease (NAFLD) and metabolic disorders, especially type-2 diabetes (T2DM), has been proven to be bidirectional. Hypoglycemic agents may be promising treatments for those disorders. However, there is currently no approved hypoglycemic therapy for NAFLD. In this review, we aimed to compare the efficacy and safety of twelve different hypoglycemic treatments in patients with NAFLD and T2DM. Methods We systematically screened randomized controlled trials (RCTs) published from March 2013 to March 2023 by searching PubMed, Embase, Medline, and Web of Science without any language restriction. We registered this project on the PROSPERO website: https://www.crd.york.ac.uk/PROSPERO/(ID: CRD42023429701). All subsequent analyses were performed under the registered protocol. The mean difference (MD) and 95% confidence interval (95% CI) were adapted to evaluate the effect size of the treatment. The surface under the cumulative sorting curve (SUCRA) was used to rank the efficacy of the included treatments. Results We included 19 trials involving 1212 patients in total. Insulin plus glucagon-like peptide-1 receptor agonist (GLP1RA) combination therapy was probably the most effective treatment for reducing weight and body mass index (BMI) (SUCRA: 0.93 and 1.00). Thiazolidinediones (TZD) were probably the most effective treatment for reducing glycosylated hemoglobin (HbA1c) and γ-glutamyltranspeptidase (γ-GGT) levels (SUCRA: 0.78 and 0.97). Sodium-glucose cotransporter 2 inhibitors (SGLT2i) had the highest probability of presenting good therapeutic efficacy in reducing triglyceride (TG) levels (SUCRA: 0.72). The most common adverse reactions were gastrointestinal disorders, mainly after the administration of GLP1RA, and mild hypoglycemia, which was closely related to the use of insulin. Conclusion GLP1RA plus insulin combination therapy, GLP1RA, SGLT2i, and TZD may be the most effective therapeutic methods for patients with NAFLD and T2DM.
- Open Access
Relationship between The Monocyte-to-High Density Lipoprotein Cholesterol Ratio (MHR) and Coronary Artery Lesions.
This study aimed to investigate the relationship between MHR and coronary artery lesions. A total of 488 patients aged 40-84 years who had undergone coronary angiography were enrolled in the study. The patients were divided into groups based on the presence or absence of coronary artery lesions and the number of branches affected. Statistical analysis using SPSS 26.0 software was conducted to examine the relationship between MHR, relevant clinical indicators, and coronary artery lesions. Additionally, the predictive value of MHR for coronary artery lesions was evaluated using the receiver operating characteristic (ROC) curve. The results revealed significantly higher MHR values in the lesioned group compared to the non-lesioned group [0.45 (0.34-0.62) vs. 0.35 (0.26-0.45), P CI 1.746 to 112.899, P=0.013). The ROC curve analysis determined that an optimal diagnostic threshold of 0.435 for MHR exhibited a sensitivity of 0.546 and a specificity of 0.740 for coronary artery lesions. In conclusion, elevated MHR levels were found to be associated with coronary artery lesions. The study demonstrated that a higher MHR level corresponded to a greater percentage of patients with coronary artery lesions, particularly in cases with a lesion branch number of 3. Therefore, MHR could serve as a valuable tool for identifying individuals at risk of developing coronary artery lesions.
Open AccessRelationship between The Monocyte-to-High Density Lipoprotein Cholesterol Ratio (MHR) and Coronary Artery Lesions.
This study aimed to investigate the relationship between MHR and coronary artery lesions. A total of 488 patients aged 40-84 years who had undergone coronary angiography were enrolled in the study. The patients were divided into groups based on the presence or absence of coronary artery lesions and the number of branches affected. Statistical analysis using SPSS 26.0 software was conducted to examine the relationship between MHR, relevant clinical indicators, and coronary artery lesions. Additionally, the predictive value of MHR for coronary artery lesions was evaluated using the receiver operating characteristic (ROC) curve. The results revealed significantly higher MHR values in the lesioned group compared to the non-lesioned group [0.45 (0.34-0.62) vs. 0.35 (0.26-0.45), P CI 1.746 to 112.899, P=0.013). The ROC curve analysis determined that an optimal diagnostic threshold of 0.435 for MHR exhibited a sensitivity of 0.546 and a specificity of 0.740 for coronary artery lesions. In conclusion, elevated MHR levels were found to be associated with coronary artery lesions. The study demonstrated that a higher MHR level corresponded to a greater percentage of patients with coronary artery lesions, particularly in cases with a lesion branch number of 3. Therefore, MHR could serve as a valuable tool for identifying individuals at risk of developing coronary artery lesions.
- Open Access
- 8 May 2023
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 24 (1) , 1-18
Trace amine-associated receptor 1 regulation of Kv1.4 channels in trigeminal ganglion neurons contributes to nociceptive behaviors
Background: Trace amines, such as tyramine, are endogenous amino acid metabolites that have been hypothesized to promote headache. However, the underlying cellular and molecular mechanisms remain unknown.Methods: Using patch-clamp recording, immunostaining, molecular biological approaches and behaviour tests, we elucidated a critically functional role of tyramine in regulating membrane excitability and pain sensitivity by manipulating Kv1.4 channels in trigeminal ganglion (TG) neurons.Results: Application of tyramine to TG neurons decreased the A-type K+current (IA) in a manner dependent on trace amine-associated receptor 1 (TAAR1). Either siRNA knockdown of Gαo or chemical inhibition of βγ subunit (Gβγ) signaling abrogated the response to tyramine. Antagonism of protein kinase C (PKC) prevented the tyramine-inducedIAresponse, while inhibition of conventional PKC isoforms or protein kinase A elicited no such effect. Tyramine increased the membrane abundance of PKCθin TG neurons, and either pharmacological or genetic inhibition of PKCθblocked the TAAR1-mediatedIAdecrease. Furthermore, PKCθ-dependentIAsuppression was mediated by Kv1.4 channels. Knockdown of Kv1.4 abrogated the TAAR1-inducedIAdecrease, neuronal hyperexcitability, and pain hypersensitivity. In a mouse model of migraine induced by electrical stimulation of the dura mater surrounding the superior sagittal sinus, blockade of TAAR1 signaling attenuated mechanical allodynia; this effect was occluded by lentiviral overexpression of Kv1.4 in TG neurons.Conclusion: These results suggest that tyramine induces Kv1.4-mediatedIAsuppression through stimulation of TAAR1 coupled to the Gβγ-dependent PKCθsignaling cascade, thereby enhancing TG neuronal excitability and mechanical pain sensitivity. Insight into TAAR1 signaling in sensory neurons provides attractive targets for the treatment of headache disorders such as migraine.
- 8 May 2023
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 24 (1) , 1-18
Open AccessTrace amine-associated receptor 1 regulation of Kv1.4 channels in trigeminal ganglion neurons contributes to nociceptive behaviors
Background: Trace amines, such as tyramine, are endogenous amino acid metabolites that have been hypothesized to promote headache. However, the underlying cellular and molecular mechanisms remain unknown.Methods: Using patch-clamp recording, immunostaining, molecular biological approaches and behaviour tests, we elucidated a critically functional role of tyramine in regulating membrane excitability and pain sensitivity by manipulating Kv1.4 channels in trigeminal ganglion (TG) neurons.Results: Application of tyramine to TG neurons decreased the A-type K+current (IA) in a manner dependent on trace amine-associated receptor 1 (TAAR1). Either siRNA knockdown of Gαo or chemical inhibition of βγ subunit (Gβγ) signaling abrogated the response to tyramine. Antagonism of protein kinase C (PKC) prevented the tyramine-inducedIAresponse, while inhibition of conventional PKC isoforms or protein kinase A elicited no such effect. Tyramine increased the membrane abundance of PKCθin TG neurons, and either pharmacological or genetic inhibition of PKCθblocked the TAAR1-mediatedIAdecrease. Furthermore, PKCθ-dependentIAsuppression was mediated by Kv1.4 channels. Knockdown of Kv1.4 abrogated the TAAR1-inducedIAdecrease, neuronal hyperexcitability, and pain hypersensitivity. In a mouse model of migraine induced by electrical stimulation of the dura mater surrounding the superior sagittal sinus, blockade of TAAR1 signaling attenuated mechanical allodynia; this effect was occluded by lentiviral overexpression of Kv1.4 in TG neurons.Conclusion: These results suggest that tyramine induces Kv1.4-mediatedIAsuppression through stimulation of TAAR1 coupled to the Gβγ-dependent PKCθsignaling cascade, thereby enhancing TG neuronal excitability and mechanical pain sensitivity. Insight into TAAR1 signaling in sensory neurons provides attractive targets for the treatment of headache disorders such as migraine.
- Open Access
- 1 January 2021
- Published by Ivyspring International Publisher in Theranostics
- Vol. 11 (19) , 9342-9357
Neuromedin B receptor stimulation of Cav3.2 T-type Ca2+ channels in primary sensory neurons mediates peripheral pain hypersensitivity
Background: Neuromedin B (Nmb) is implicated in the regulation of nociception of sensory neurons. However, the underlying cellular and molecular mechanisms remain unknown.
- 1 January 2021
- Published by Ivyspring International Publisher in Theranostics
- Vol. 11 (19) , 9342-9357
Open AccessNeuromedin B receptor stimulation of Cav3.2 T-type Ca2+ channels in primary sensory neurons mediates peripheral pain hypersensitivity
Background: Neuromedin B (Nmb) is implicated in the regulation of nociception of sensory neurons. However, the underlying cellular and molecular mechanisms remain unknown.
- 13 August 2018
- Published by Wiley in Journal of Diabetes
- Vol. 11 (4) , 309-315
Peripheral pain is enhanced by insulin‐like growth factor 1 and its receptors in a mouse model of type 2 diabetes mellitus
Background Insulin‐like growth factor‐1 (IGF‐1) is a multidimensional neurotrophic factor. Nevertheless, it has been reported that IGF‐1 may lead to hyperalgesia. This study aimed to investigate the effects of IGF‐1 on the overall behaviour of diabetic mice and to explore the possible mechanisms of IGF‐1‐induced pain effects. Methods The mice were divided into five groups: db/m group, db/db group, db/db+vehicle group, IGF‐1‐treated db/db group and IGF‐1‐JB‐1‐treated db/db group. Behavioural studies were conducted using the hot plate and Von Frey tests after intraplantar injection of recombinant insulin‐like growth factor‐1 (rIGF‐1) and IGF‐1 receptor (IGF‐1R) antagonist. Morphological changes in the dorsal root ganglia (DRG) were observed using electron microscopy. IGF‐1R expression and co‐localisation with pain mediators in the DRG were detected using immunofluorescence. Changes in the expression of IGF‐1R, extracellular signal regulation kinase (ERK), and ras‐associated factor‐1 (c‐raf) in the DRG were detected by western blotting. Results Intraplantar injection of rIGF‐1 resulted in a hyperalgesic effect after two hours. This IGF‐1‐induced hypersensitivity was attenuated by pre‐intraplantar injection of an IGF‐1R antagonist. There was no significant change in neuronal structure in the db/m group, whereas the other four groups were impaired. Moreover, IGF‐1R was co‐localised with pain mediators in DRG of mice. Intraplantar injection of rIGF‐1 resulted in the increased expression of IGF‐1R, p‐ERK and c‐raf in DRG, and pre‐intraplantar injection of an IGF‐1R antagonist attenuated the level of p‐ERK and c‐raf. Conclusions IGF‐1‐induced acute hyperalgesia may be associated with the IGF‐R/c‐raf/ERK pathway. This IGF‐1‐induced hypersensitivity was attenuated after using an IGF‐1R antagonist.
- 13 August 2018
- Published by Wiley in Journal of Diabetes
- Vol. 11 (4) , 309-315
Peripheral pain is enhanced by insulin‐like growth factor 1 and its receptors in a mouse model of type 2 diabetes mellitus
Background Insulin‐like growth factor‐1 (IGF‐1) is a multidimensional neurotrophic factor. Nevertheless, it has been reported that IGF‐1 may lead to hyperalgesia. This study aimed to investigate the effects of IGF‐1 on the overall behaviour of diabetic mice and to explore the possible mechanisms of IGF‐1‐induced pain effects. Methods The mice were divided into five groups: db/m group, db/db group, db/db+vehicle group, IGF‐1‐treated db/db group and IGF‐1‐JB‐1‐treated db/db group. Behavioural studies were conducted using the hot plate and Von Frey tests after intraplantar injection of recombinant insulin‐like growth factor‐1 (rIGF‐1) and IGF‐1 receptor (IGF‐1R) antagonist. Morphological changes in the dorsal root ganglia (DRG) were observed using electron microscopy. IGF‐1R expression and co‐localisation with pain mediators in the DRG were detected using immunofluorescence. Changes in the expression of IGF‐1R, extracellular signal regulation kinase (ERK), and ras‐associated factor‐1 (c‐raf) in the DRG were detected by western blotting. Results Intraplantar injection of rIGF‐1 resulted in a hyperalgesic effect after two hours. This IGF‐1‐induced hypersensitivity was attenuated by pre‐intraplantar injection of an IGF‐1R antagonist. There was no significant change in neuronal structure in the db/m group, whereas the other four groups were impaired. Moreover, IGF‐1R was co‐localised with pain mediators in DRG of mice. Intraplantar injection of rIGF‐1 resulted in the increased expression of IGF‐1R, p‐ERK and c‐raf in DRG, and pre‐intraplantar injection of an IGF‐1R antagonist attenuated the level of p‐ERK and c‐raf. Conclusions IGF‐1‐induced acute hyperalgesia may be associated with the IGF‐R/c‐raf/ERK pathway. This IGF‐1‐induced hypersensitivity was attenuated after using an IGF‐1R antagonist.
- Open Access
- 26 March 2013
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 14 (4) , 6746-6756
The Protective Effects of α-Lipoic Acid on Kidneys in Type 2 Diabetic Goto-Kakisaki Rats via Reducing Oxidative Stress
To evaluate the protective effects of α-lipoic acid on the kidneys of Goto-Kakisaki (GK) diabetic rats, ten GK diabetic rats were randomly divided into a diabetic control group and a lipoic acid-treated diabetic group with α-lipoic acid 35 mg·Kg−1 intraperitoneal injections. Four healthy Wistar rats served as normal controls. Malonaldehyde (MDA), ascorbic acid (vitamin C), vitamin E, glutathione (GSH) and superoxide dismutase (SOD) levels in renal homogenate, and urine protein excretion were measured. The expression of mRNA for NF-κB, NADPH oxidase subunits p22phox and p47phox in renal tissue was examined by realtime PCR. Pathological changes in renal tissue were evaluated by light and electron microscopy. There were significant increases in urine protein excretion, MDA levels and the expression of mRNA of NF-κB, p22phox and p47phox, and significant decreases in GSH, SOD, vitamin C and vitamin E levels in the diabetic control group compared with the normal control group. Pathological changes of renal tissue were more progressive in the diabetic control group than in the normal control group. All the parameters above were improved in the α-lipoic acid-treated diabetic group. Oxidative stress is increased in the kidney of type 2 diabetic GK rats. It is associated with the progression of diabetic nephropathy. α-lipoic acid can protect renal function in diabetic rats via its antioxidant activity.
- 26 March 2013
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 14 (4) , 6746-6756
Open AccessThe Protective Effects of α-Lipoic Acid on Kidneys in Type 2 Diabetic Goto-Kakisaki Rats via Reducing Oxidative Stress
To evaluate the protective effects of α-lipoic acid on the kidneys of Goto-Kakisaki (GK) diabetic rats, ten GK diabetic rats were randomly divided into a diabetic control group and a lipoic acid-treated diabetic group with α-lipoic acid 35 mg·Kg−1 intraperitoneal injections. Four healthy Wistar rats served as normal controls. Malonaldehyde (MDA), ascorbic acid (vitamin C), vitamin E, glutathione (GSH) and superoxide dismutase (SOD) levels in renal homogenate, and urine protein excretion were measured. The expression of mRNA for NF-κB, NADPH oxidase subunits p22phox and p47phox in renal tissue was examined by realtime PCR. Pathological changes in renal tissue were evaluated by light and electron microscopy. There were significant increases in urine protein excretion, MDA levels and the expression of mRNA of NF-κB, p22phox and p47phox, and significant decreases in GSH, SOD, vitamin C and vitamin E levels in the diabetic control group compared with the normal control group. Pathological changes of renal tissue were more progressive in the diabetic control group than in the normal control group. All the parameters above were improved in the α-lipoic acid-treated diabetic group. Oxidative stress is increased in the kidney of type 2 diabetic GK rats. It is associated with the progression of diabetic nephropathy. α-lipoic acid can protect renal function in diabetic rats via its antioxidant activity.